JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Effects of Mediterranean Diet Intervention in Diabetic Heart Disease

  NCT03757845

  Conditions:   Diabetes Complications;   Cardiovascular Diseases
  Intervention:   Other: Mediterranean Diet
  Sponsor:   Maine Medical Center
  Recruiting
• Neuroinflammatory Response and Headache Control in Patients After Subarachnoid Hemorrhage

  NCT03604276

  Conditions:   Subarachnoid Hemorrhage, Aneurysmal;   Headache;   Subarachnoid Hemorrhage
  Intervention:  
  Sponsor:   Maine Medical Center
  Recruiting
• Treatment of HFpEF With Nitrate Supplement

  NCT03289481

  Condition:   Heart Failure With Normal Ejection Fraction
  Interventions:   Dietary Supplement: Active lozenge;   Drug: Placebo
  Sponsors:   Penobscot Bay Medical Center;   HumanN
  Completed
• Study to Evaluate the Effectiveness of SGB in Preventing Post-op Atrial Fibrillation

  NCT03269383

  Condition:   Atrial Fibrillation
  Interventions:   Drug: Bupivacaine;   Other: Saline
  Sponsor:   Christopher Connors, MD
  Withdrawn
• Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?

  NCT03219294

  Condition:   Arthropathy of Hip
  Interventions:   Drug: Vecuronium 0.1 mg/kg;   Drug: Vecuronium 0.2mg/kg
  Sponsors:   Craig Curry;   Maine Medical Center;   Spectrum Medical Group Anesthesiology
  Completed
• Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery

  NCT02919436

  Condition:   Post-operative Urinary Retention
  Interventions:   Drug: Tamsulosin;   Drug: Placebo
  Sponsor:   Maine Medical Center
  Recruiting
• Studies of Neuregulin/ERBB Signaling in Human Heart

  NCT02820233

  Conditions:   Heart Disease;   Vascular Disease;   Heart Failure
  Intervention:  
  Sponsors:   Douglas B. Sawyer;   Maine Medical Center
  Recruiting
• Phase 1 Study of HBN-1

  NCT04094857

  Condition:   Cardiac Arrest
  Intervention:   Drug: HBN-1
  Sponsor:   Hibernaid, Inc
  Not yet recruiting
• Online Mindfulness-based Tic Reduction (Phase Two)

  NCT03771235

  Conditions:   Tourette Syndrome;   Persistent Tic Disorder
  Interventions:   Behavioral: Mindfulness-based Intervention for Tics;   Behavioral: Tic Information and Coping Strategies
  Sponsors:   Bowdoin College;   Massachusetts General Hospital
  Recruiting
• Online Mindfulness-based Tic Reduction

  NCT03525626

  Conditions:   Tourette Syndrome;   Tic Disorders
  Intervention:   Behavioral: Online Mindfulness-based Tic Reduction
  Sponsors:   Bowdoin College;   Massachusetts General Hospital
  Completed
• A Community Health Worker Program to Support Rural Older Adults

  NCT03843333

  Conditions:   Frail Elderly;   Cognitive Impairment;   Mobility Limitation;   Depressive Symptoms
  Interventions:   Behavioral: Tai Ji Quan: Moving for Better Balance;   Behavioral: Behavioral Activation;   Other: Resource Navigation;   Other: Enhanced Usual Care
  Sponsors:   University of Vermont;   Central Vermont Medical Center;   Dartmouth College;   Dartmouth-Hitchcock Medical Center;   Maine Medical Center;   MaineGeneral Health;   Maine-Dartmouth Family Medicine Residency;   Dartmouth SYNERGY Clinical and Translational Science Institute;   Northern New England Clinical and Translational Research Network
  Recruiting
• OMT to Improve Feeding After Hypothermia

  NCT03380013

  Conditions:   Neonatal Encephalopathy;   Feeding; Difficult, Newborn
  Intervention:   Procedure: Osteopathic Manipulative Treatment (OMT)
  Sponsor:   Maine Medical Center
  Completed
• Study of TOP1630 for Dry Eye Syndrome

  NCT03833388

  Condition:   Dry Eye Syndrome
  Interventions:   Drug: TOP1630 0.1% Ophthalmic Solution TID OU;   Drug: Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
  Sponsor:   Topivert Pharma Ltd
  Completed
• HOBSCOTCH Phase II

  NCT02394509

  Condition:   Epilepsy
  Intervention:   Behavioral: Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)
  Sponsors:   Dartmouth-Hitchcock Medical Center;   Centers for Disease Control and Prevention
  Active, not recruiting
• A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease

  NCT04084483

  Condition:   Dry Eye Disease
  Interventions:   Drug: K-161;   Other: Placebo (Vehicle)
  Sponsor:   Kowa Research Institute, Inc.
  Recruiting
• Cenobamate Open-Label Extension Study for YKP3089C025

  NCT03961568

  Condition:   Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
  Intervention:   Drug: Cenobamate
  Sponsor:   SK Life Science, Inc.
  Enrolling by invitation
• Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

  NCT01234766

  Condition:   Lymphoma, Follicular
  Interventions:   Drug: Bendamustine;   Drug: Rituximab;   Radiation: Y-90 ibritumomab
  Sponsors:   Dartmouth-Hitchcock Medical Center;   Cephalon;   Spectrum Pharmaceuticals, Inc
  Active, not recruiting
• Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

  NCT01886872

  Conditions:   CD19 Positive;   CD20 Positive;   CD5 Positive;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
  Interventions:   Drug: Bendamustine Hydrochloride;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

  NCT03737981

  Condition:   Chronic Lymphocytic Leukemia
  Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Observation;   Drug: Venetoclax
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

  NCT03633331

  Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Promoting Informed Decisions About Cancer Screening in Older Adults

  NCT03959696

  Condition:   Colorectal Cancer Screening
  Interventions:   Behavioral: Notification;   Behavioral: Training
  Sponsors:   Massachusetts General Hospital;   Maine Medical Center;   Brigham and Women's Hospital;   Newton-Wellesley Hospital;   North Shore Medical Center
  Enrolling by invitation
• A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

  NCT01960010

  Condition:   Dry Eye Syndromes
  Interventions:   Drug: MIM-D3 Ophthalmic Solution;   Drug: Vehicle
  Sponsor:   Mimetogen Pharmaceuticals USA, Inc.
  Completed
• Targeting Inflammation Using Salsalate in CardioVascular Disease

  NCT00624923

  Conditions:   Coronary Artery Disease;   Overweight
  Interventions:   Drug: Salsalate;   Drug: Placebo
  Sponsors:   Joslin Diabetes Center;   Beth Israel Deaconess Medical Center;   Tufts Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
  Completed
• Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer

  NCT03811002

  Conditions:   Limited Stage Lung Small Cell Carcinoma;   Stage I Lung Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Atezolizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

  NCT03775265

  Conditions:   Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall;   Bladder Urothelial Carcinoma;   Stage II Bladder Cancer AJCC v8;   Stage III Bladder Cancer AJCC v8;   Stage IIIA Bladder Cancer AJCC v8
  Interventions:   Drug: Atezolizumab;   Drug: Cisplatin;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Mitomycin;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Other: Survey Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414

  Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
  Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445

  Condition:   Previously Treated Non-Small Cell Lung Cancer
  Intervention:   Drug: Screening Platform
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER

  NCT03371719

  Conditions:   PSA Progression;   Stage III Prostate Adenocarcinoma;   Stage IV Prostate Adenocarcinoma
  Interventions:   Drug: Apalutamide;   Radiation: External Beam Radiation Therapy;   Other: Placebo
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

  NCT03499808

  Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
  Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

  NCT03244384

  Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

  NCT03382561

  Conditions:   Extensive Stage Lung Small Cell Carcinoma;   Recurrent Lung Small Cell Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

  NCT03055013

  Conditions:   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Adrenal Gland;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Malignant Neoplasm in the Pancreas;   Metastatic Malignant Neoplasm in the Skin;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Unclassified Renal Cell Carcinoma
  Interventions:   Procedure: Conventional Surgery;   Biological: Nivolumab;   Other: Patient Observation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

  NCT02954874

  Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  NCT03092674

  Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2
  Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Midostaurin;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559

  Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  NCT02785952

  Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

  NCT02595944

  Conditions:   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Intervention:   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

  NCT02997228

  Conditions:   Colorectal Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

  NCT03488693

  Condition:   Breast Cancer
  Interventions:   Radiation: Radiation;   Other: No Radiation
  Sponsors:   Canadian Cancer Trials Group;   Alliance for Clinical Trials in Oncology;   Eastern Cooperative Oncology Group;   NRG Oncology;   Southwest Oncology Group
  Recruiting
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992

  Conditions:   ALK Gene Rearrangement;   ALK Gene Translocation;   ALK Positive;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

  NCT02196181

  Conditions:   BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

  NCT02154490

  Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Other: Pharmacological Study;   Biological: Rilotumumab;   Drug: Talazoparib;   Drug: Taselisib;   Biological: Tremelimumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

  NCT02032823

  Condition:   Breast Cancer
  Interventions:   Drug: Olaparib;   Drug: Placebo
  Sponsors:   AstraZeneca;   Breast International Group;   Frontier Science & Technology Research Foundation, Inc.;   NRG Oncology;   Myriad Genetic Laboratories, Inc.;   Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet;   Merck Sharp & Dohme Corp.
  Active, not recruiting
• Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer

  NCT02364557

  Conditions:   Dyspnea;   Fatigue;   Nausea and Vomiting;   Pain;   Stage IV Breast Cancer
  Interventions:   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery

  NCT03033576

  Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

  NCT02785913

  Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Taselisib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

  NCT01674140

  Condition:   Breast Cancer
  Interventions:   Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Cardiovascular Inflammation Reduction Trial

  NCT01594333

  Condition:   Cardiovascular Disease
  Interventions:   Drug: Methotrexate;   Drug: Placebo
  Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
  Completed
• Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

  NCT02115282

  Conditions:   Breast Adenocarcinoma;   HER2/Neu Negative;   Locally Advanced Breast Carcinoma;   Metastatic Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin;   Drug: Goserelin Acetate;   Other: Placebo;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

  NCT02019264

  Conditions:   Cardiovascular Disease;   High Cardiovascular Risk;   Obesity;   Overweight;   Type 2 Diabetes
  Interventions:   Drug: Lorcaserin hydrochloride;   Drug: Placebo
  Sponsors:   Eisai Inc.;   Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization
  Completed
• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

  NCT01275677

  Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7
  Interventions:   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

  NCT01901094

  Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
  Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

  NCT01272037

  Conditions:   Ductal Breast Carcinoma In Situ;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
  Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

  NCT03367702

  Condition:   Stage II Prostate Adenocarcinoma
  Interventions:   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Radiation: Stereotactic Body Radiation Therapy (SBRT)
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

  NCT03180268

  Conditions:   Grade II Meningioma;   Intracranial Meningioma
  Interventions:   Other: Clinical Observation;   Radiation: Radiation Therapy
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

  NCT03009981

  Condition:   Prostate Cancer
  Interventions:   Drug: Apalutamide;   Drug: LHRH Analogue;   Drug: Abiraterone Acetate;   Drug: Prednisone
  Sponsors:   Alliance Foundation Trials, LLC.;   Janssen Research & Development, LLC
  Recruiting
• Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

  NCT02929329

  Condition:   Heart Failure
  Interventions:   Drug: Omecamtiv Mecarbil;   Drug: Placebo
  Sponsors:   Amgen;   Cytokinetics;   Servier
  Active, not recruiting
• FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

  NCT02890355

  Conditions:   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer AJCC v6 and v7
  Interventions:   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

  NCT02595905

  Conditions:   Breast Carcinoma Metastatic in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

  NCT02506153

  Conditions:   Metastatic Cutaneous Melanoma;   Metastatic Non-Cutaneous Melanoma;   Non-Cutaneous Melanoma;   Recurrent Cutaneous Melanoma;   Recurrent Non-Cutaneous Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage III Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7
  Interventions:   Biological: Ipilimumab;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249

  Condition:   Kidney Cancer
  Interventions:   Drug: everolimus;   Other: placebo
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

  NCT02152982

  Conditions:   Glioblastoma;   Gliosarcoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Temozolomide;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

  NCT00310180

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIB Breast Cancer AJCC v7
  Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen Citrate
  Sponsors:   National Cancer Institute (NCI);   American College of Surgeons;   Cancer and Leukemia Group B;   NSABP Foundation Inc;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
  Active, not recruiting
• Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805

  Conditions:   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Cisplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Pemetrexed Disodium;   Other: Questionnaire Administration;   Drug: Vinorelbine Tartrate
  Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
  Active, not recruiting
• Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT02048813

  Conditions:   Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
  Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Biological: Rituximab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery

  NCT00326898

  Conditions:   Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer AJCC v6 and v7;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Sorafenib Tosylate;   Drug: Sunitinib Malate
  Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   Southwest Oncology Group
  Completed
• Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

  NCT02004275

  Condition:   Multiple Myeloma in Relapse
  Interventions:   Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
  Recruiting
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

  NCT01975389

  Condition:   Cardiovascular Disease
  Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
  Sponsor:   Pfizer
  Terminated
• Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

  NCT01953588

  Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
  Interventions:   Drug: fulvestrant;   Drug: anastrozole
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  NCT01950390

  Conditions:   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
  Interventions:   Biological: Bevacizumab;   Biological: Ipilimumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

  NCT01949337

  Conditions:   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
  Interventions:   Drug: enzalutamide;   Drug: abiraterone;   Drug: prednisone
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Astellas Pharma US, Inc.;   Medivation, Inc.;   Biologics, Inc.
  Active, not recruiting
• Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

  NCT00769379

  Condition:   Ductal Breast Carcinoma In Situ
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

  NCT01903811

  Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
  Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

  NCT01764633

  Condition:   Dyslipidemia
  Interventions:   Biological: Evolocumab;   Drug: Placebo
  Sponsor:   Amgen
  Completed
• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

  NCT01575548

  Conditions:   Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v7
  Interventions:   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive and High-Risk, Lymph Node-Negative Breast Cancer

  NCT00433511

  Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
  Interventions:   Biological: Bevacizumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Paclitaxel;   Other: Placebo
  Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   ECOG-ACRIN Cancer Research Group;   North Central Cancer Treatment Group
  Active, not recruiting
• Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

  NCT01169337

  Conditions:   Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
  Interventions:   Other: Clinical Observation;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

  NCT00878709

  Condition:   Breast Cancer
  Interventions:   Drug: neratinib;   Other: placebo
  Sponsor:   Puma Biotechnology, Inc.
  Active, not recruiting
• Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

  NCT00785291

  Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIC Breast Cancer AJCC v6;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Biological: Bevacizumab;   Drug: Ixabepilone;   Other: Laboratory Biomarker Analysis;   Drug: Nab-paclitaxel;   Drug: Paclitaxel;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

  NCT00443274

  Condition:   Breast Implant
  Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
  Sponsor:   Allergan
  Recruiting
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

  NCT03678025

  Conditions:   Castration Levels of Testosterone;   Metastatic Prostatic Adenocarcinoma;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
  Interventions:   Drug: Abiraterone;   Drug: Bicalutamide;   Drug: Degarelix;   Drug: Docetaxel;   Drug: Flutamide;   Drug: Goserelin Acetate;   Drug: Histrelin Acetate;   Drug: Leuprolide Acetate;   Drug: Nilutamide;   Procedure: Orchiectomy;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Procedure: Radical Prostatectomy;   Drug: Triptorelin
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer

  NCT03660826

  Conditions:   Endometrial Undifferentiated Carcinoma;   Endometrioid Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IV Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
  Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737

  Conditions:   Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Lynch Syndrome;   Stage IIA Colon Cancer AJCC v7;   Stage IIB Colon Cancer AJCC v7;   Stage IIC Colon Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer

  NCT03199885

  Conditions:   Breast Adenocarcinoma;   Metastatic Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Atezolizumab;   Drug: Paclitaxel;   Biological: Pertuzumab;   Other: Placebo;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

  NCT03155997

  Condition:   Breast Cancer
  Interventions:   Drug: Abemaciclib;   Drug: Standard Adjuvant Endocrine Therapy
  Sponsors:   Eli Lilly and Company;   NSABP Foundation Inc
  Active, not recruiting
• Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS

  NCT02926911

  Conditions:   DCIS;   Ductal Carcinoma in Situ
  Interventions:   Other: Guideline Concordant Care;   Other: Active Surveillance
  Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute;   Duke University;   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   New York University;   Washington University School of Medicine
  Recruiting
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

  NCT02867813

  Condition:   Dyslipidemia
  Intervention:   Biological: Evolocumab
  Sponsor:   Amgen
  Active, not recruiting
• Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02839707

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Undifferentiated Carcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Undifferentiated Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Suspended
• Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

  NCT02839343

  Conditions:   Pancreatic Adenocarcinoma;   Borderline Resectable Adenocarcinoma of the Head of the Pancrease
  Interventions:   Radiation: radiation therapy;   Procedure: surgery;   Drug: mFOLFIRINOX;   Drug: FOLFOX
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Sky Foundation
  Active, not recruiting
• A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006

  Condition:   Renal Cell Cancer
  Interventions:   Drug: Avelumab (MSB0010718C);   Drug: Axitinib (AG-013736);   Drug: Sunitinib
  Sponsor:   Pfizer
  Active, not recruiting
• informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

  NCT02582879

  Condition:   Chronic Lymphocytic Leukemia (CLL)
  Intervention:  
  Sponsors:   Pharmacyclics LLC.;   Janssen, LP
  Active, not recruiting
• Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02502266

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan;   Drug: Topotecan Hydrochloride
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02446600

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Tumor;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Tumor;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Ovarian Endometrioid Adenocarcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   AstraZeneca;   NRG Oncology
  Active, not recruiting
• Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  NCT02339571

  Conditions:   Recurrent Cutaneous Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab;   Biological: Sargramostim
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

  NCT02311933

  Conditions:   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Tamoxifen Citrate;   Drug: Z-Endoxifen Hydrochloride
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

  NCT02164916

  Condition:   Colorectal Cancer
  Interventions:   Biological: cetuximab;   Drug: irinotecan hydrochloride;   Drug: vemurafenib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Roche-Genentech
  Active, not recruiting
• Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

  NCT01856192

  Conditions:   Ann Arbor Stage II Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage III Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

  NCT01854918

  Condition:   Hyperlipidemia and Mixed Dyslipidemia
  Interventions:   Biological: Evolocumab;   Drug: Standard of Care
  Sponsor:   Amgen
  Completed
• Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

  NCT01835158

  Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Kidney Carcinoma;   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7
  Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Drug: Sunitinib Malate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

  NCT01809691

  Condition:   Prostate Cancer
  Interventions:   Drug: TAK-700;   Drug: Bicalutamide
  Sponsors:   Southwest Oncology Group;   Millennium Pharmaceuticals, Inc.;   National Cancer Institute (NCI)
  Active, not recruiting
• A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

  NCT01772472

  Condition:   Breast Cancer
  Interventions:   Drug: trastuzumab;   Drug: trastuzumab emtansine
  Sponsors:   Hoffmann-La Roche;   NSABP Foundation Inc;   German Breast Group
  Active, not recruiting
• LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

  NCT01763866

  Condition:   Hyperlipidemia
  Interventions:   Biological: Evolocumab;   Drug: Ezetimibe;   Drug: Placebo to Evolocumab;   Drug: Placebo to Ezetimibe;   Drug: Atorvastatin;   Drug: Rosuvastatin;   Drug: Simvastatin
  Sponsor:   Amgen
  Completed
• Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

  NCT01415752

  Conditions:   Lymphoma;   Neurotoxicity;   Therapy-related Toxicity
  Interventions:   Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Drug: lenalidomide
  Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

  NCT01286272

  Conditions:   Ann Arbor Stage III Grade 1 Follicular Lymphoma;   Ann Arbor Stage III Grade 2 Follicular Lymphoma;   Ann Arbor Stage III Grade 3 Follicular Lymphoma;   Ann Arbor Stage IV Grade 1 Follicular Lymphoma;   Ann Arbor Stage IV Grade 2 Follicular Lymphoma;   Ann Arbor Stage IV Grade 3 Follicular Lymphoma;   Grade 3a Follicular Lymphoma
  Interventions:   Drug: Bendamustine Hydrochloride;   Drug: Bortezomib;   Radiation: Fludeoxyglucose F-18;   Other: Laboratory Biomarker Analysis;   Biological: Ofatumumab;   Procedure: Positron Emission Tomography with Radiolabeled Targeting Agent
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

  NCT01196390

  Conditions:   Esophageal Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Stage IB Esophageal Cancer AJCC v7;   Stage IIA Esophageal Cancer AJCC v7;   Stage IIB Esophageal Cancer AJCC v7;   Stage IIIA Esophageal Cancer AJCC v7;   Stage IIIB Esophageal Cancer AJCC v7
  Interventions:   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

  NCT00951496

  Conditions:   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Carcinoma;   Stage IIA Fallopian Tube Cancer AJCC v6 and v7;   Stage IIA Ovarian Cancer AJCC V6 and v7;   Stage IIB Fallopian Tube Cancer AJCC v6 and v7;   Stage IIB Ovarian Cancer AJCC v6 and v7;   Stage IIC Fallopian Tube Cancer AJCC v6 and v7;   Stage IIC Ovarian Cancer AJCC v6 and v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

  NCT00942331

  Conditions:   Advanced Urothelial Carcinoma;   Metastatic Bladder Urothelial Carcinoma;   Metastatic Prostate Carcinoma;   Metastatic Renal Pelvis Urothelial Carcinoma;   Metastatic Ureter Urothelial Carcinoma;   Metastatic Urethral Urothelial Carcinoma;   Metastatic Urothelial Carcinoma;   Stage IV Bladder Urothelial Carcinoma AJCC v7;   Stage IV Prostate Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7;   Unresectable Urothelial Carcinoma
  Interventions:   Biological: Bevacizumab;   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

  NCT00644228

  Conditions:   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
  Interventions:   Drug: Bortezomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

  NCT00601900

  Conditions:   Invasive Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v6;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Questionnaire Administration;   Drug: Tamoxifen Citrate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer

  NCT00219557

  Condition:   Pancreatic Neoplasms
  Interventions:   Drug: Gemcitabine;   Drug: AG-013736
  Sponsor:   Pfizer
  Completed
• Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

  NCT03088813

  Condition:   Small Cell Lung Cancer
  Interventions:   Drug: Irinotecan liposome injection;   Drug: Topotecan
  Sponsor:   Ipsen
  Recruiting
• A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

  NCT03988114

  Condition:   Metastatic Breast Cancer
  Interventions:   Drug: Abemaciclib;   Drug: Nonsteroidal Aromatase Inhibitor (NSAI)
  Sponsor:   Eli Lilly and Company
  Withdrawn
• Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

  NCT03793179

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma

  NCT03788746

  Condition:   Urothelial Carcinoma
  Intervention:  
  Sponsor:   AstraZeneca
  Recruiting
• Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery

  NCT03757949

  Condition:   Bladder Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Dietary Supplement: Nutritional Intervention;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)

  NCT03737994

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Alectinib;   Drug: Brigatinib;   Drug: Carboplatin;   Drug: Ceritinib;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Ensartinib;   Drug: Lorlatinib;   Drug: Pemetrexed
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma

  NCT03422003

  Condition:   Breast Cancer
  Intervention:   Radiation: Radiation Therapy
  Sponsors:   Dana-Farber Cancer Institute;   Patient-Centered Outcomes Research Institute
  Recruiting
• Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

  NCT03701308

  Condition:   Acute Myeloid Leukemia
  Interventions:   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Uproleselan
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

  NCT03698019

  Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
  Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223

  Condition:   Acute Coronary Syndrome
  Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
  Sponsor:   CSL Behring
  Recruiting
• Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

  NCT03348631

  Conditions:   FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma;   Recurrent Endometrial Endometrioid Adenocarcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Ovarian Clear Cell Adenocarcinoma;   Recurrent Ovarian Endometrioid Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Tazemetostat
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Suspended
• Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

  NCT03274687

  Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Adenocarcinoma;   Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
  Interventions:   Radiation: Hypofractionated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

  NCT02921256

  Conditions:   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7
  Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Biological: Pembrolizumab;   Drug: Veliparib
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Suspended
• Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes

  NCT02856581

  Condition:   Lung Carcinoma
  Interventions:   Drug: Varenicline;   Drug: Placebo;   Other: Tobacco Cessation Counseling
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Pfizer
  Recruiting
• Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

  NCT02836873

  Condition:   Type 2 Diabetes Mellitus
  Interventions:   Drug: Bexagliflozin;   Drug: Placebo
  Sponsor:   Theracos
  Completed
• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  NCT02834013

  Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
  Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

  NCT02783573

  Condition:   Alzheimer's Disease
  Interventions:   Drug: Lanabecestat;   Drug: Placebo
  Sponsors:   Eli Lilly and Company;   AstraZeneca
  Terminated
• The National Myelodysplastic Syndromes (MDS) Study

  NCT02775383

  Condition:   Myelodysplastic Syndromes (MDS)
  Intervention:   Other: Therapeutic
  Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
  Recruiting
• CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

  NCT02670083

  Condition:   Alzheimer's Disease
  Interventions:   Drug: Crenezumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Completed
• Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

  NCT02554890

  Condition:   Acute Heart Failure
  Interventions:   Drug: sacubitril/valsartan (LCZ696);   Drug: Enalapril;   Drug: sacubitril/valsartan (LCZ696) matching placebo;   Drug: enalapril matching placebo
  Sponsor:   Novartis Pharmaceuticals
  Completed
• Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

  NCT02547818

  Condition:   Alzheimer's Disease
  Interventions:   Drug: ALZT-OP1a;   Drug: ALZT-OP1b;   Other: Placebo ALZT-OP1a;   Other: Placebo ALZT-OP1b
  Sponsors:   AZTherapies, Inc.;   PharmaConsulting Group;   KCAS Bio;   APCER Life Sciences
  Active, not recruiting
• PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

  NCT02513394

  Condition:   Breast Cancer
  Interventions:   Drug: Palbociclib;   Drug: Standard Adjuvant Endocrine Therapy
  Sponsors:   Alliance Foundation Trials, LLC.;   Austrian Breast & Colorectal Cancer Study Group;   NSABP Foundation Inc;   PrECOG, LLC.;   Breast International Group;   Pfizer
  Active, not recruiting
• A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

  NCT02451137

  Condition:   Diabetes Mellitus, Type 2
  Interventions:   Drug: Insulin glargine, 300 U/ml;   Drug: Insulin glargine, 100 U/ml;   Drug: Insulin detemir;   Drug: Background Therapy
  Sponsor:   Sanofi
  Completed
• Absorb IV Randomized Controlled Trial

  NCT02173379

  Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
  Interventions:   Device: Absorb BVS;   Device: XIENCE
  Sponsor:   Abbott Medical Devices
  Active, not recruiting
• Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

  NCT02027428

  Condition:   Squamous Cell Carcinoma, Non-Small-Cell Lung
  Interventions:   Drug: Abraxane (Induction);   Drug: Carboplatin (Induction);   Drug: Abraxane (Maintenance);   Other: Best Supportive Care (Maintenance)
  Sponsor:   Celgene
  Completed
• Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

  NCT02003222

  Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

  NCT02003209

  Conditions:   HER2/Neu Positive;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7
  Interventions:   Drug: Aromatase Inhibition Therapy;   Drug: Carboplatin;   Other: Cytology Specimen Collection Procedure;   Drug: Docetaxel;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

  NCT01920711

  Condition:   Heart Failure With Preserved Ejection Fraction
  Interventions:   Drug: LCZ696;   Drug: Valsartan
  Sponsor:   Novartis Pharmaceuticals
  Completed
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

  NCT01900665

  Condition:   Alzheimer's Disease
  Interventions:   Drug: Solanezumab;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Terminated
• Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

  NCT01872975

  Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
  Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
  Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

  NCT01822509

  Conditions:   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma
  Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

  NCT01822496

  Conditions:   Stage III Non-Small Cell Lung Cancer AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7;   Stage IIIB Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Radiation: Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Erlotinib;   Drug: Etoposide;   Drug: Paclitaxel
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Terminated
• ABSORB III Randomized Controlled Trial (RCT)

  NCT01751906

  Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
  Interventions:   Device: Absorb BVS;   Device: XIENCE
  Sponsor:   Abbott Medical Devices
  Completed
• A Study of Evacetrapib in High-Risk Vascular Disease

  NCT01687998

  Condition:   Cardiovascular Diseases
  Interventions:   Drug: Evacetrapib;   Drug: Placebo
  Sponsors:   Eli Lilly and Company;   The Cleveland Clinic
  Terminated
• Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment

  NCT01573442

  Conditions:   Arthralgia;   Breast Cancer;   Hot Flashes;   Musculoskeletal Complications;   Sexual Dysfunction
  Interventions:   Drug: testosterone;   Other: placebo
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer

  NCT01556243

  Condition:   Breast Cancer
  Interventions:   Procedure: therapeutic conventional surgery;   Radiation: whole breast irradiation
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia

  NCT01535053

  Conditions:   Choriocarcinoma;   FIGO Stage I Gestational Trophoblastic Tumor;   FIGO Stage II Gestational Trophoblastic Tumor;   FIGO Stage III Gestational Trophoblastic Tumor;   Hydatidiform Mole
  Interventions:   Biological: Dactinomycin;   Drug: Leucovorin Calcium;   Drug: Methotrexate;   Other: Quality-of-Life Assessment
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

  NCT01515787

  Condition:   Colorectal Cancer
  Interventions:   Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Active, not recruiting
• S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

  NCT01498289

  Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
  Interventions:   Drug: FOLFOX regimen;   Drug: docetaxel;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Open Label Study of Long Term Evaluation Against LDL-C Trial

  NCT01439880

  Condition:   Hypercholesterolemia
  Interventions:   Biological: Evolocumab;   Other: Standard of care
  Sponsor:   Amgen
  Completed
• Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

  NCT01420926

  Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Therapy-Related Acute Myeloid Leukemia
  Interventions:   Drug: Bortezomib;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

  NCT01358877

  Condition:   Breast Cancer
  Interventions:   Drug: 5-Fluorouracil;   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Doxorubicin;   Drug: Epirubicin;   Drug: Paclitaxel;   Drug: Pertuzumab;   Drug: Placebo;   Drug: Trastuzumab
  Sponsors:   Hoffmann-La Roche;   Genentech, Inc.;   Breast International Group
  Active, not recruiting
• Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

  NCT01256398

  Conditions:   Acute Lymphoblastic Leukemia;   Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
  Interventions:   Biological: Alemtuzumab;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide Phosphate;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Melphalan;   Drug: Mercaptopurine;   Drug: Methotrexate;   Biological: Pegfilgrastim;   Other: Pharmacological Study;   Drug: Tacrolimus;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

  NCT01253070

  Conditions:   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11;   Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   Acute Promyelocytic Leukemia With PML-RARA;   FLT3 Gene Mutation;   Therapy-Related Acute Myeloid Leukemia
  Interventions:   Procedure: Biopsy;   Procedure: Bone Marrow Aspiration;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01238211

  Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   Core Binding Factor Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
  Interventions:   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

  NCT01167712

  Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer AJCC v6 and v7;   Stage IIA Ovarian Cancer AJCC V6 and v7;   Stage IIB Fallopian Tube Cancer AJCC v6 and v7;   Stage IIB Ovarian Cancer AJCC v6 and v7;   Stage IIC Fallopian Tube Cancer AJCC v6 and v7;   Stage IIC Ovarian Cancer AJCC v6 and v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7;   Stage IV Fallopian Tube Cancer AJCC v6 and v7;   Stage IV Ovarian Cancer AJCC v6 and v7;   Stage IV Primary Peritoneal Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Procedure: Computed Tomography;   Drug: Paclitaxel;   Procedure: Therapeutic Conventional Surgery
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

  NCT01145495

  Conditions:   Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Ann Arbor Stage III Grade 1 Follicular Lymphoma;   Ann Arbor Stage III Grade 2 Follicular Lymphoma;   Ann Arbor Stage III Grade 3 Follicular Lymphoma;   Ann Arbor Stage IV Grade 1 Follicular Lymphoma;   Ann Arbor Stage IV Grade 2 Follicular Lymphoma;   Ann Arbor Stage IV Grade 3 Follicular Lymphoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Rituximab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• PRE-DETERMINE Cohort Study

  NCT01114269

  Conditions:   Coronary Artery Disease;   Left Ventricular Dysfunction;   Sudden Cardiac Death
  Intervention:  
  Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   Abbott Medical Devices;   Northwestern University;   Roche Diagnostics;   Quintiles, Inc.
  Active, not recruiting
• A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

  NCT01101438

  Condition:   Breast Cancer
  Interventions:   Drug: metformin hydrochloride;   Other: placebo
  Sponsors:   Canadian Cancer Trials Group;   National Cancer Institute (NCI);   International Breast Cancer Study Group;   ICR-CTSU
  Active, not recruiting
• Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

  NCT00887146

  Condition:   Brain and Central Nervous System Tumors
  Interventions:   Drug: concomitant temozolomide (TMZ);   Radiation: radiotherapy;   Drug: procarbazine;   Drug: adjuvant temozolomide (TMZ);   Drug: CCNU;   Drug: vincristine
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   European Organisation for Research and Treatment Center (EORTC);   Canadian Cancer Trials Group
  Recruiting
• Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

  NCT00884741

  Conditions:   Glioblastoma;   Gliosarcoma;   Supratentorial Glioblastoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Biological: Bevacizumab;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Temozolomide
  Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   NRG Oncology
  Completed
• Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

  NCT00770809

  Conditions:   Male Breast Carcinoma;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Drug: Paclitaxel;   Biological: Trastuzumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

  NCT00693992

  Conditions:   Stage IIIB Lung Non-Small Cell Cancer AJCC v7;   Stage IV Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Sunitinib Malate
  Sponsor:   National Cancer Institute (NCI)
  Completed
• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

  NCT00490139

  Condition:   Neoplasms, Breast
  Interventions:   Drug: Lapatinib;   Biological: Trastuzumab
  Sponsors:   Novartis Pharmaceuticals;   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Breast International Group;   Canadian Cancer Trials Group
  Active, not recruiting
• Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

  NCT00390455

  Conditions:   Estrogen Receptor Positive;   HER2 Positive Breast Carcinoma;   HER2/Neu Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Fulvestrant;   Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

  NCT00262847

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
  Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Completed
• Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

  NCT00262821

  Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
  Interventions:   Drug: cisplatin;   Drug: tirapazamine
  Sponsors:   National Cancer Institute (NCI);   NCIC Clinical Trials Group;   Gynecologic Oncology Group
  Terminated
• Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

  NCT00262600

  Conditions:   Atrial Fibrillation;   Stroke
  Interventions:   Drug: warfarin;   Drug: Dabigatran dose 1;   Drug: Dabigatran dose 2
  Sponsors:   Boehringer Ingelheim;   Population Health Research Institute;   Uppsala University
  Completed
• Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

  NCT00070499

  Condition:   Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  Interventions:   Drug: Dasatinib;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690

  Conditions:   Estrogen Receptor Positive Breast Cancer;   Progesterone Receptor Positive Tumor;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer
  Interventions:   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Procedure: Oophorectomy;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen;   Drug: Triptorelin
  Sponsors:   International Breast Cancer Study Group;   Breast International Group;   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   NSABP Foundation Inc;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
  Active, not recruiting
• Symptom Management Implementation of Patient Reported Outcomes in Oncology

  NCT03850912

  Conditions:   Other Cancer;   Gastrointestinal Cancer;   Thoracic Cancer;   Gynecologic Cancer
  Interventions:   Other: eSyM App Usage;   Other: SASS Questionnaire
  Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI);   RTI International;   Baptist Memorial Health Care Corporation;   Dartmouth-Hitchcock Medical Center;   Maine Medical Center;   West Virginia University;   Lifespan
  Not yet recruiting
• Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients With AsYmptomatic Severe Aortic Stenosis

  NCT03042104

  Conditions:   Aortic Stenosis;   Heart Diseases
  Intervention:   Device: Edwards SAPIEN 3 THV
  Sponsor:   Edwards Lifesciences
  Recruiting
• Diuretic Comparison Project

  NCT02185417

  Condition:   Hypertension
  Interventions:   Drug: Hydrochlorothiazide (HCTZ);   Drug: Chlorthalidone
  Sponsor:   VA Office of Research and Development
  Recruiting
• A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

  NCT03404115

  Condition:   Dry Eye Syndrome
  Interventions:   Drug: Reproxalap Ophthalmic Solution (0.25%);   Drug: Reproxalap Ophthalmic Solution (0.1%);   Drug: Vehicle Ophthalmic Solution
  Sponsor:   Aldeyra Therapeutics, Inc.
  Completed
• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

  NCT03907488

  Conditions:   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IIIA Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Classic Hodgkin Lymphoma;   Lymphocyte-Rich Classic Hodgkin Lymphoma
  Interventions:   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Biological: Nivolumab;   Biological: Pegfilgrastim;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Vinblastine;   Drug: Vinblastine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296

  Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Intervention:   Drug: Rucaparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

  NCT03377556

  Conditions:   ATM Gene Mutation;   ATR Gene Mutation;   BARD1 Gene Mutation;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   BRIP1 Gene Mutation;   CHEK1 Gene Mutation;   CHEK2 Gene Mutation;   FANCA Gene Mutation;   FANCC Gene Mutation;   FANCD2 Gene Mutation;   FANCF Gene Mutation;   FANCM Gene Mutation;   NBN Gene Mutation;   PALB2 Gene Mutation;   RAD51 Gene Mutation;   RAD51B Gene Mutation;   RAD54L Gene Mutation;   Recurrent Squamous Cell Lung Carcinoma;   RPA1 Gene Mutation;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

  NCT01274338

  Conditions:   Melanoma of Unknown Primary;   Recurrent Melanoma;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
  Interventions:   Biological: Ipilimumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

  NCT01598298

  Conditions:   Breast Cancer;   Musculoskeletal Complications;   Pain
  Interventions:   Drug: duloxetine hydrochloride;   Other: placebo
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Completed
• Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

  NCT03609021

  Conditions:   Breast Carcinoma;   Estrogen Receptor Negative;   Progesterone Receptor Negative
  Interventions:   Procedure: Screening Mammography;   Procedure: Biospecimen Collection
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Interleukin 6 Blockade Modifying Antibody-Mediated Graft Injury and Estimated Glomerular Filtration Rate (eGFR) Decline

  NCT03744910

  Condition:   Antibody-mediated Rejection
  Interventions:   Biological: Clazakizumab;   Drug: Normal saline
  Sponsors:   Vitaeris INC;   ICON Clinical Research
  Recruiting
• Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma

  NCT03632135

  Condition:   Recurrent Glioblastoma
  Interventions:   Diagnostic Test: ChemoID assay;   Drug: Chemotherapy
  Sponsor:   Cordgenics, LLC
  Recruiting
• Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

  NCT01627041

  Conditions:   Acute Myeloid Leukemia;   Adult Acute Basophilic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
  Interventions:   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

  NCT02764541

  Condition:   Breast Cancer
  Interventions:   Drug: Letrozole;   Drug: Tamoxifen;   Drug: Palbociclib;   Drug: Endocrine Therapy
  Sponsors:   Dana-Farber Cancer Institute;   Pfizer
  Recruiting
• Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

  NCT02441686

  Condition:   Multiple Myeloma
  Interventions:   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
  Sponsors:   Dana-Farber Cancer Institute;   Millennium Pharmaceuticals, Inc.;   Celgene
  Active, not recruiting
• Ureteral Stent Placement After Ureteroscopy for Renal Stones: A Randomized Controlled Trial

  NCT03855787

  Condition:   Kidney Calculi
  Intervention:   Procedure: Ureteroscopy
  Sponsors:   Vanderbilt University Medical Center;   University of Michigan;   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   Maine Medical Center;   Mayo Clinic;   Université de Montréal;   University of California, Davis;   University of California, San Diego
  Not yet recruiting
• ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

  NCT03587740

  Condition:   Breast Cancer
  Intervention:   Drug: T-DM1
  Sponsors:   Dana-Farber Cancer Institute;   Susan G. Komen Breast Cancer Foundation;   Gateway for Cancer Research
  Recruiting
• PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation

  NCT01402063

  Condition:   Glioblastoma Multiforme
  Interventions:   Drug: PPX (CT2103);   Drug: Temozolomide
  Sponsors:   Brown University;   Rhode Island Hospital;   Milton S. Hershey Medical Center;   University of Washington;   University of Massachusetts, Worcester;   Maine Medical Center;   University of California, San Diego;   Thomas Jefferson University
  Completed
• Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

  NCT03180684

  Conditions:   Vulvar High Grade Squamous Intraepithelial Lesion (HSIL);   Vulvar Dysplasia;   Vulvar Intraepithelial Neoplasia (VIN);   VIN2;   VIN3;   Pre-cancerous Lesions of the Vulva;   Human Papillomavirus (HPV)
  Interventions:   Biological: VGX-3100;   Drug: Imiquimod 5% cream;   Device: CELLECTRA™ 2000
  Sponsor:   Inovio Pharmaceuticals
  Active, not recruiting
• Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

  NCT03180502

  Conditions:   1p/19q Co-deletion;   Anaplastic Astrocytoma;   Diffuse Astrocytoma;   Glioma;   IDH1 Gene Mutation;   IDH2 Gene Mutation;   Oligoastrocytoma;   Oligodendroglioma;   WHO Grade III Glioma
  Interventions:   Radiation: IMRT (Intensity-Modulated Radiation Therapy);   Radiation: Proton Beam Radiation Therapy;   Drug: Temozolomide
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

  NCT03941483

  Condition:   Acute Kidney Injury (AKI)
  Interventions:   Drug: ASP1128;   Drug: Placebo
  Sponsor:   Astellas Pharma Inc
  Recruiting
• Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

  NCT03898180

  Condition:   Urothelial Carcinoma
  Interventions:   Biological: Pembrolizumab;   Drug: Lenvatinib;   Drug: Placebo for lenvatinib
  Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc.
  Recruiting
• A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

  NCT01602380

  Condition:   Hormone Receptor Positive Breast Cancer
  Interventions:   Drug: faslodex 500mg;   Drug: arimidex 1mg;   Drug: faslodex dummy;   Drug: arimidex dummy
  Sponsor:   AstraZeneca
  Active, not recruiting
• Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

  NCT03629249

  Conditions:   Asthma;   Bronchial Diseases;   Respiratory Tract Diseases;   Lung Diseases, Obstructive;   Lung Diseases;   Respiratory Hypersensitivity;   Hypersensitivity, Immediate;   Hypersensitivity;   Immune System Diseases;   Physiological Effects of Drugs
  Interventions:   Drug: Placebo;   Drug: QAW039 Dose 1;   Drug: QAW039 Dose 2
  Sponsor:   Novartis Pharmaceuticals
  Recruiting